Neurocysticercosis Clinical Trial
Official title:
Open Controled Randomized Pilot Study on the Use of Acetazolamide and Dexamethasone for the Acute Phase of Perilesional Edema in Calcified Neurocysticercosis
Verified date | April 2019 |
Source | Universidad Peruana Cayetano Heredia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Three-arm open, randomized comparative study of acetazolamide, dexamethasone, or no additional treatment to evaluate decrease in peri-calcification edema in neurocysticercosis
Status | Terminated |
Enrollment | 4 |
Est. completion date | December 2018 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Calcified NCC - Perilesional edema on CT or MRI - Normal lab values Exclusion Criteria: - Viable neurocysticercosis - Status epilepticus - Symptomatic intracranial hypertension - Tuberculosis - More than 7 days after seizure - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Peru | Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas | Lima |
Lead Sponsor | Collaborator |
---|---|
Universidad Peruana Cayetano Heredia |
Peru,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Decrease in Volume of Perilesional Edema Between Baseline and Day 4 | MRI extension of edema | Baseline to Day 4 | |
Secondary | Decrease in Volume of Perilesional Edema Between Baseline and Day 8 | MRI extension of edema | Baseline to Day 8 | |
Secondary | Decrease in Volume of Perilesional Edema Between Baseline and Day 30 | MRI extension of edema | Baseline to Day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00527579 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
|
Phase 1 | |
Completed |
NCT00526916 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
|
Phase 1 | |
Terminated |
NCT02233855 -
People Presenting With Neurocysticercosis in North America
|
||
Recruiting |
NCT00001205 -
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
|
||
Completed |
NCT02234570 -
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
|
Phase 1 | |
Terminated |
NCT02947581 -
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
|
Phase 3 | |
Completed |
NCT02243644 -
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
|
Phase 3 | |
Not yet recruiting |
NCT06376396 -
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
|
Phase 4 | |
Completed |
NCT03874689 -
Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
|
||
Completed |
NCT00441285 -
Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04706819 -
Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
|
||
Completed |
NCT00283699 -
A Pilot Study of Neurocysticercosis Treatment
|
Phase 3 | |
Completed |
NCT00290823 -
Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
|
Phase 3 | |
Completed |
NCT03834337 -
Treatment of Patients With Active Neurocysticercosis in Eastern Africa
|
||
Completed |
NCT03851419 -
The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
|